RMED - Ra Medical Systems, Inc.

NYSE - NYSE Delayed Price. Currency in USD
5.05
+0.59 (+13.23%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close4.46
Open4.48
Bid5.01 x 1800
Ask4.90 x 800
Day's Range4.42 - 5.08
52 Week Range3.34 - 22.00
Volume251,943
Avg. Volume104,561
Market Cap64.827M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-3.34
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est11.75
Trade prices are not sourced from all markets
  • Business Wire13 days ago

    DABRA Excimer Laser Atherectomy to be Presented in Key Events at Charing Cross International Symposium

    Ra Medical Systems, Inc. today announced the schedule of key DABRA Excimer Laser Atherectomy events at the upcoming Charing Cross International Symposium in London April 16–18.

  • Business Wirelast month

    Ra Medical Systems Reports 2018 Fourth Quarter and Full Year Financial Results

    Introduces new integrated commercial strategy to support physician adoption of the DABRA laser system and build long-term customer relationshipsConference call begins at 4:30 pm Ea

  • Business Wire2 months ago

    New Study Shows DABRA Laser System Achieved 94% Success Rate in Patients with Peripheral Artery Disease

    Ra Medical Systems, Inc. , today announced study results from Athar Ansari, MD, Director of the California Heart & Vascular Clinic, who stated, “DABRA is fundamentally changing the way I practice medicine.” Dr.

  • Business Wire2 months ago

    Ra Medical to Hold 2018 Fourth Quarter and Full Year Conference Call on March 14, 2019

    Ra Medical Systems, Inc. announces that it will report 2018 fourth quarter and full year financial results after market close on Thursday, March 14, 2019. Ra Medical management will hold an investment community conference call at 4:30 p.m.

  • Business Wire2 months ago

    New Data Presented at LINC 2019 Demonstrates Acute Success with DABRA Excimer Laser System for the Treatment of Peripheral Artery Disease

    The study results were overwhelmingly positive, given the inclusion of a challenging sample of patients, all Rutherford class 4 to 6 with a high presence of calcium (80% of lesions had moderate to severe calcification) and 93% median lesion stenosis. “The results of this study are extremely promising and demonstrate the positive clinical outcomes we have seen with DABRA,” said Dr. Kondur, Chair, Division of Cardiology, Garden City Hospital/MSU and Associate Program Director, Interventional Cardiology Fellowship Program, DMC Harper University Hospital, Wayne State University.

  • Business Wire4 months ago

    Ra Medical Systems to Present at Biotech Showcase 2019 on January 8 during Annual JPMorgan Healthcare Conference in San Francisco

    Ra Medical Systems, Inc. (RMED), a medical device company focusing on commercializing excimer laser systems to treat tough vascular and dermatological diseases, announces that CEO Dean Irwin will present at the 11th Annual Biotech Showcase on January 8, 2019, in San Francisco. Mr. Irwin will present an overview of Ra Medical’s business, technology and strategic growth objectives, including the commercialization of its excimer laser system, DABRA™, which is FDA-cleared to cross chronic total occlusions in patients with symptomatic infrainguinal lower extremity vascular disease.

  • Analysts Expect Breakeven For Ra Medical Systems, Inc. (NYSE:RMED)
    Simply Wall St.4 months ago

    Analysts Expect Breakeven For Ra Medical Systems, Inc. (NYSE:RMED)

    Ra Medical Systems, Inc.'s (NYSE:RMED): Ra Medical Systems, Inc., a commercial-stage medical device company, develops, manufactures, and markets excimer lasers for use in the treatment of vascular and dermatological diseases. Read More...

  • Business Wire4 months ago

    Ra Medical Systems Appoints Thomas Fogarty as Chief Commercial Officer

    Mr. Fogarty brings over two decades of medical device leadership and commercialization experience to Ra Medical Systems and will oversee all aspects of the Company's commercialization efforts, which include the sales and marketing of its proprietary excimer laser systems that treat tough vascular and dermatological diseases. “Over the years, Tom has demonstrated a proven track record leading both early-stage companies and large corporations through commercialization and sales growth,” said Dean Irwin, Chief Executive Officer, Ra Medical Systems.

  • Business Wire5 months ago

    Ra Medical Systems Reports Third Quarter 2018 Results

    -Revenue increased nearly 60% year-over-year to $2.1 million

  • Business Wire6 months ago

    Ra Medical Systems to Report Third Quarter 2018 Results on November 13, 2018

    Ra Medical Systems, Inc. (RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases, announced that it will release its financial results for the three-month period ended September 30, 2018 on Tuesday, November 13, 2018 after the market close. The Company will host a conference call with the investment community on Tuesday, November 13th, at 2:00 p.m. Pacific Time / 5:00 p.m. Eastern Time featuring remarks by Dean Irwin, Chief Executive Officer and Andrew Jackson, Chief Financial Officer. The dial-in numbers for the conference call are +1-877-407-4018 (U.S. Toll Free) or +1-201-689-8471 (International).

  • Business Wire6 months ago

    Ra Medical Systems Appoints Dan Horwood as General Counsel

    Ra Medical Systems, Inc. (RMED), a commercial-stage medical device company leveraging its advanced excimer laser-based platform for use in the treatment of vascular and dermatological diseases, announced today that it has appointed Dan Horwood as General Counsel, effective immediately. Mr. Horwood brings nearly two decades of corporate and securities experience to Ra Medical and will oversee all aspects of the Company’s legal activities and policies. “Dan’s deep experience advising publicly listed companies on corporate matters makes him an ideal and timely choice for Ra Medical.

  • Business Wire7 months ago

    Ra Medical Systems Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares

    Ra Medical Systems, Inc. today announced the closing of its initial public offering of 4,485,000 shares of common stock, which includes the full exercise of the underwriters’ option to purchase 585,000 additional shares of its common stock, at a price to the public of $17 per share.

  • Business Wire7 months ago

    Ra Medical Systems Announces Pricing of Initial Public Offering

    Ra Medical Systems, Inc. (RMED) today announced the pricing of its initial public offering of 3,900,000 shares of common stock at a price to the public of $17.00 per share. In addition, Ra Medical has granted the underwriters a 30-day option to purchase up to an additional 585,000 shares of common stock at the initial public offering price less underwriting discounts and commissions. Ra Medical’s common stock is expected to begin trading on the New York Stock Exchange under the symbol “RMED” on September 27, 2018.

  • Benzinga7 months ago

    The IPO Outlook For The Week: Smart Appliances, A Language App and Drugmakers

    For a more comprehensive IPO calendar, check out the offering in Benzinga Cloud . Viomi Technology Co., Ltd ( VIOT ) will issue 11.4 million shares between $9 and $11 Tuesday on the Nasdaq. Headquartered ...